# OnCo record localised-anal-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/localised-anal-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "localised-anal-cancer" ;
  schema:name "Localised anal squamous cell carcinoma (stage I to III)"@en ;
  schema:alternateName "Non-metastatic anal cancer"@en, "Locoregional anal squamous cell carcinoma"@en, "Anal canal cancer treated with chemoradiotherapy"@en, "Stage I to III anal cancer"@en ;
  schema:description "Localised anal cancer is squamous cell cancer of the anal canal that has not spread beyond the pelvis and groin, one of the few cancers cured mainly by chemotherapy and radiotherapy together rather than by surgery. Fluorouracil with mitomycin during radiotherapy has been standard since the ACT II trial; surgery to remove the anus is kept for the minority whose cancer persists or returns."@en ;
  schema:url <https://onco.cc/cancers/localised-anal-cancer/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anal_cancer> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(13)70086-X>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414>, <https://en.wikipedia.org/wiki/Anal_cancer> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/anal-hsil-precursor/>, <https://onco.cc/cancers/metastatic-anal-cancer/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/locally-advanced-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:drugs <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:terms <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/chemoradiation/> ;
  onco:trials <https://onco.cc/trials/act-ii/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013/>, <https://onco.cc/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/> ;
  onco:pipeline <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:standardOfCare <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/trials/act-ii/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/trials/act-ii/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/nivolumab/> .